Advances in the management of basal cell carcinoma

Lewin, John M.; Carucci, John A.

doi:10.12703/p7-53

Cited by 39 publications

(38 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study observed a success rate of 89% for ED&C. Although finding the success rate of ED&C was not the primary purpose of this study, our success rate correlates well with previous research showing success rates between 84 and 98% [6,7,10,11] . There are several potential confounding variables.…”

Section: Discussionsupporting

confidence: 88%

Early Detection of Desiccation and Curettage Failure in the Treatment of Basal Cell Carcinoma

Woldow

Melvin²

2016

Dermatology

View full text Add to dashboard Cite

Background/Aims: Basal cell carcinoma (BCC) is a malignant neoplasm of keratinocytes. Electrodessication and curettage (ED&C) published cure rates vary widely, and the authors of this study are unaware of any previous literature which has attempted to rapidly identify treatment failures. Objective: To identify BCC ED&C failures by histologically analyzing the fragments produced by the third round of curettage. Methods: The monitoring of routine therapy of 862 cases of BCC that were treated by ED&C followed by the submission of cautery fragments of the third round of curettage for histological and immunohistochemical testing. Results: Of the 862 cases, 764 (89%) had no residual BCC seen in their curetting. Of these patients, zero recurrences (0%) were noted. Forty-eight of the 862 cases had residual BCC seen in their curetting and elected to receive no additional therapy. Eighteen (38%) had a recurrence detected. Fifty of the 862 cases had residual BCC seen in their curetting and elected for immediate re-excision. Thirty-five (70%) had histological evidence of residual BCC. Limitations: The study was performed at a single center with 2 years of follow-up. Conclusion: Pathological examination of curettage fragments in combination with immunohistochemistry testing appears to be beneficial in predicting which patients are likely to have recurrence of BCC after ED&C.

show abstract

Section: Discussionsupporting

confidence: 88%

Early Detection of Desiccation and Curettage Failure in the Treatment of Basal Cell Carcinoma

Woldow

Melvin²

2016

Dermatology

View full text Add to dashboard Cite

show abstract

“…BCC is derived from non-keratinizing cells of the basal layer of the epidermis, generally grows slowly and rarely metastasizes [30]. Current treatment options of BCC include standard excision, Mohs micrographic surgery, electrodesiccation and curettage, cryosurgery, radiation therapy, photodynamic therapy, 5-fluorouracil or imiquimod (an immune modifier) and for extensive cases hedgehog signaling pathway inhibitors such as vismodegib [31]. SCC accounts for about 20% of non-melanoma skin cancers and originates from squamous cells of the epidermis, typically forming slowly growing nodules which may ulcerate.…”

Section: Introductionmentioning

confidence: 99%

Synthetic Peptide Drugs for Targeting Skin Cancer: Malignant Melanoma and Melanotic Lesions

Eberlé

Rout

et al. 2017

CMC

View full text Add to dashboard Cite

Peptides play decisive roles in the skin, ranging from host defense responses to various forms of neuroendocrine regulation of cell and organelle function. Synthetic peptides conjugated to radionuclides or photosensitizers may serve to identify and treat skin tumors and their metastatic forms in other organs of the body. In the introductory part of this review, the role and interplay of the different peptides in the skin are briefly summarized, including their potential application for the management of frequently occurring skin cancers. Special emphasis is given to different targeting options for the treatment of melanoma and melanotic lesions. Radionuclide Targeting: α-Melanocyte-stimulating hormone (α-MSH) is the most prominent peptide for targeting of melanoma tumors via the G protein-coupled melanocortin-1 receptor that is (over-)expressed by melanoma cells and melanocytes. More than 100 different linear and cyclic analogs of α-MSH containing chelators for 111In, 67/68Ga, 64Cu, 90Y, 212Pb, 99mTc, 188Re were synthesized and examined with experimental animals and in a few clinical studies. Linear Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 (NAP-amide) and Re-cyclized Cys- Cys-Glu-His-D-Phe-Arg-Trp-Cys-Arg-Pro-Val-NH2 (Re[Arg11]CCMSH) containing different chelators at the N- or C-terminus served as lead compounds for peptide drugs with further optimized characteristics. Alternatively, melanoma may be targeted with radiopeptides that bind to melanin granules occurring extracellularly in these tumors. Photosensitizer targeting: A more recent approach is the application of photosensitizers attached to the MSH molecule for targeted photodynamic therapy using LED or coherent laser light that specifically activates the photosensitizer. Experimental studies have demonstrated the feasibility of this approach as a more gentle and convenient alternative compared to radionuclides.

show abstract

“…The lifetime risk of developing NMSC is estimated to be one in five, with the majority of cases being basal cell carcinoma (BCC). 1 Incidence of BCC increases with age, with the main risk factor being ultraviolet exposure. 2 Patients with a diagnosed BCC are at significantly higher risk of developing subsequent lesions.…”

Section: What Does This Study Add?mentioning

confidence: 99%

A phase I clinical trial demonstrates that nfP2X₇ -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma

Gilbert

Baird²,

Glazer³

et al. 2017

Br J Dermatol

View full text Add to dashboard Cite

SummaryBackground Expression of P2X 7 , an ATP-gated calcium channel, increases cancer cell proliferation and invasiveness. A variant of P2X 7 (termed nfP2X 7 ), in which a normally hidden epitope (E200) is exposed for antibody binding, is observed in a variety of different cancers. Objectives To investigate the safety, tolerability and pharmacokinetics and assess indicative efficacy of a novel antibody ointment as a therapeutic for basal cell carcinoma (BCC). Methods An open-label, phase I clinical trial was undertaken at three dermatology clinics to evaluate the safety and tolerability of topical administration of an ointment containing 10% sheep polyclonal anti-nfP2X 7 antibodies (BIL010t) to primary BCC lesions twice daily for 28 days. Twenty-one patients with primary BCC lesions at least 0Á5 cm 2 in area and less than 2Á0 cm in diameter were enrolled. The primary end points were safety, tolerability and pharmacokinetics. Change in lesion size after treatment was determined and histology was performed on pretreatment and end-of-treatment (EOT) biopsies. Results Compliance was very high, with treatment being well tolerated. The most common adverse events were treatment site erythema, pruritus, dryness and pain. There was no evidence of systemic penetration of the sheep antibody. Lesions were measured prior to and after 28 days of treatment, with 65% of patients showing a reduction in lesion area, 20% showing no change and 15% showing an increase. Histopathology of post-treatment excision of lesion sites showed eight patients with stable disease, nine with partial response and three with complete response. Conclusions Antibodies against nfP2X 7 (BIL010t) provide a novel, safe and welltolerated treatment for BCC.

show abstract

Advances in the management of basal cell carcinoma

Cited by 39 publications

References 64 publications

Early Detection of Desiccation and Curettage Failure in the Treatment of Basal Cell Carcinoma

Early Detection of Desiccation and Curettage Failure in the Treatment of Basal Cell Carcinoma

Synthetic Peptide Drugs for Targeting Skin Cancer: Malignant Melanoma and Melanotic Lesions

A phase I clinical trial demonstrates that nfP2X₇ -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma

Contact Info

Product

Resources

About

Advances in the management of basal cell carcinoma

Cited by 39 publications

References 64 publications

Early Detection of Desiccation and Curettage Failure in the Treatment of Basal Cell Carcinoma

Early Detection of Desiccation and Curettage Failure in the Treatment of Basal Cell Carcinoma

Synthetic Peptide Drugs for Targeting Skin Cancer: Malignant Melanoma and Melanotic Lesions

A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma

Contact Info

Product

Resources

About

A phase I clinical trial demonstrates that nfP2X₇ -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma